Dermapharm Holding (Germany) Today
| DMP Stock | 40.05 0.25 0.63% |
Performance14 of 100
| Odds Of DistressLess than 9
|
Dermapharm Holding is selling for under 40.05 as of the 13th of January 2025; that is 0.63 percent increase since the beginning of the trading day. The stock's last reported lowest price was 39.55. Dermapharm Holding has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 14th of December 2024 and ending today, the 13th of January 2025. Click here to learn more.
Moving against Dermapharm Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Dermapharm Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Dermapharm Holding's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Dermapharm Holding or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
Dermapharm Holding SE (DMP) is traded on XETRA Stock Exchange in Germany and employs 2,373 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.1 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dermapharm Holding's market, we take the total number of its shares issued and multiply it by Dermapharm Holding's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Dermapharm Holding operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. The entity has 53.84 M outstanding shares.
Dermapharm Holding SE has accumulated about 161.38 M in cash with 250.37 M of positive cash flow from operations.
Check Dermapharm Holding Probability Of Bankruptcy
Ownership AllocationDermapharm Holding holds a total of 53.84 Million outstanding shares. Dermapharm Holding SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.04 percent of Dermapharm Holding outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Dermapharm Ownership Details
Dermapharm Holding Risk Profiles
Although Dermapharm Holding's alpha and beta are two of the key measurements used to evaluate Dermapharm Holding's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.45 | |||
| Semi Deviation | 1.27 | |||
| Standard Deviation | 2.09 | |||
| Variance | 4.37 |
Dermapharm Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Dermapharm Holding without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Dermapharm Holding Corporate Management
Elected by the shareholders, the Dermapharm Holding's board of directors comprises two types of representatives: Dermapharm Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dermapharm. The board's role is to monitor Dermapharm Holding's management team and ensure that shareholders' interests are well served. Dermapharm Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dermapharm Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Britta Hamberger | Head Communications | Profile | |
| HansGeorge Feldmeier | CEO Board | Profile | |
| Christof Dreibholz | Chief Officer | Profile | |
| Karin Samusch | Member Officer | Profile | |
| Andreas Eberhorn | Chief Officer | Profile |
Additional Tools for Dermapharm Stock Analysis
When running Dermapharm Holding's price analysis, check to measure Dermapharm Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermapharm Holding is operating at the current time. Most of Dermapharm Holding's value examination focuses on studying past and present price action to predict the probability of Dermapharm Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermapharm Holding's price. Additionally, you may evaluate how the addition of Dermapharm Holding to your portfolios can decrease your overall portfolio volatility.